GENE THERAPY
-
Health Canada approves Hemgenix gene therapy for hemophilia B
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the...
-
New shared decision-making tool (SDM) by the World Federation of Hemophilia
The World Federation of Hemophilia SDM Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between people with hemophilia A or...
-
Update on gene therapy for hemophilia
Montreal, August 10, 2023 – Gene therapies for hemophilia A and B continue to move closer to becoming reality. Health Canada is currently evaluating two...
-
Important survey about hemophilia B gene therapy – THE CLOCK IS TICKING!
The 1st gene therapy for hemophilia B (factor IX deficiency) is currently undergoing an evaluation by Canadian health authorities. This review will determine whether or...
-
2022 CHS Annual Report
Please CLICK HERE to access the 2022 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking HERE.